Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection

Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection

Background & Aims: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and antiviral activity of selgantolimod (a Toll-l...

Full description

Bibliographic Details
Main Authors: Harry L. Janssen, Young-Suk Lim, Hyung Joon Kim, Leonard Sowah, Cheng-Hao Tseng, Carla S. Coffin, Magdy Elkhashab, Sang Hoon Ahn, Anh-Hoa Nguyen, Diana Chen, Jeffrey J. Wallin, Simon P. Fletcher, Circe McDonald, Jenny C. Yang, Anuj Gaggar, Diana M. Brainard, Scott Fung, Yoon Jun Kim, Jia-Horng Kao, Wan-Long Chuang, Anna E. Brooks, P. Rod Dunbar
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:JHEP Reports
Subjects:
Hepatitis B virus
oral antiviral
small molecule
immunotherapy
HBV cure
toll-like receptor
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923003063

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923003063

Similar Items